Researchers from UB and UGR, with wide experience in medicinal chemistry, have designed, synthesized, and pharmacologically characterized a set of compounds showing analgesic activity without sedative side effects.<\/p>\n
Pain remains one of the leading causes of disability worldwide, with a substantial economic and social burden. While current analgesics for moderate and acute pain, such as paracetamol and ibuprofen, are effective and widely available, existing treatments for chronic pain still present significant limitations, due to either lack of efficacy or severe side effects.<\/p>\n
For instance, first-line treatments for neuropathic pain, such as gabapentinoids offer very limited effectiveness and produce significant dizziness and sleepiness, which limits adherence to treatment.The global pain management drugs market was valued at approximately US$ 80.000 million in 2023 and is projected to reach US$ 120.000 million by 2033, Within this, chronic pain segment is expected to reach US$ 75.000 million in 2034.<\/p>\n
This landscape demonstrates a growing demand for safer and more effective alternatives, particularly in the management of neuropathic pain. This represents a significant opportunity. Innovative solutions addressing this unmet need represent a significant business opportunity for potential partners.<\/p>\n
Forty compounds with unprecedented 2-imidazolin phosphonate structure have been designed and synthesized giving rise to a robust Markush formula. The ADME profiles of selected candidates have been assessed to de-risk their development.<\/p>\n
5 representative compounds have shown analgesic activity in capsaicin-induced secondary mechanical allodynia murine model, which is known to be predictive of drug effects in neuropathic pain. In addition, compounds show clear dose-response effects with a high potency.<\/p>\n
Moreover, one of the tested compounds does not exhibit motor coordination impairments, which as previously mentioned, are among the side effects commonly associated with gabapentinoid-type analgesics.<\/p>\n
At this moment, our asset it is situated in TRL3.<\/p>\n","protected":false},"excerpt":{"rendered":"
Executive summary Researchers from UB and UGR, with wide experience in medicinal chemistry, have designed, synthesized, and pharmacologically characterized a…<\/p>\n","protected":false},"author":2,"featured_media":17398,"parent":1399,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-tecnologies.php","meta":{"_acf_changed":false,"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-23525","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/pages\/23525","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/comments?post=23525"}],"version-history":[{"count":4,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/pages\/23525\/revisions"}],"predecessor-version":[{"id":23535,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/pages\/23525\/revisions\/23535"}],"up":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/pages\/1399"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/media\/17398"}],"wp:attachment":[{"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/media?parent=23525"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}